Drug Profile
PRX OTC
Alternative Names: PRX-OTCLatest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator PhaseRx
- Class Enzymes
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inborn urea cycle disorders
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Inborn urea cycle disorders in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Inborn-urea-cycle-disorders in USA
- 25 Apr 2017 The European Medicines Agency's Committee for Orphan Medicinal Products issues a positive opinion recommending Orphan Drug status for PRX OTC for Inborn urea cycle disorders (ornithine transcarbamylase deficiency) in European Union